Status:
RECRUITING
Effects of Mesenchymal Stem Cell Supernatant on Prevention and Treatment of Skin/Mucosal Injury in Hematology Patients
Lead Sponsor:
The General Hospital of Western Theater Command
Conditions:
Mucositis
Hematopoietic Stem Cell Transplantation
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
This clinical trial is studying the effects of mesenchymal stem cell (MSC) culture supernatant on the prevention and treatment of mucosal injuries in patients undergoing hematopoietic stem cell transp...
Detailed Description
This clinical trial aims to evaluate the efficacy and safety of mesenchymal stem cell (MSC) culture supernatant in the prevention and treatment of mucosal injuries in patients undergoing hematopoietic...
Eligibility Criteria
Inclusion
- Participants aged 18 years or older.
- Patients who have undergone hematopoietic stem cell transplantation (HSCT).
- Patients who have developed mucosal injuries (oral, skin, or bladder) after HSCT, chemotherapy, or radiotherapy.
- Patients who are willing to provide informed consent and comply with the study procedures.
Exclusion
- Patients with severe organ dysfunction (e.g., heart, liver, kidney failure) that could interfere with the study.
- Patients with uncontrolled active infections.
- Known allergies or hypersensitivity to MSC supernatant.
- Pregnant or breastfeeding women.
- Patients with HIV or active hepatitis B or C infections.
- Patients who have participated in another clinical trial within the last 4 weeks.
Key Trial Info
Start Date :
October 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 30 2025
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT06599346
Start Date
October 1 2020
End Date
September 30 2025
Last Update
September 19 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Hematology, The General Hospital of Western Theater Command
Chengdu, Sichuan, China, 610083